loading
Alnylam Pharmaceuticals Inc stock is traded at $251.15, with a volume of 656.24K. It is down -2.79% in the last 24 hours and up +3.24% over the past month. Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$258.35
Open:
$259.92
24h Volume:
656.24K
Relative Volume:
0.71
Market Cap:
$33.82B
Revenue:
$2.35B
Net Income/Loss:
$-269.70M
P/E Ratio:
-120.17
EPS:
-2.09
Net Cash Flow:
$-75.39M
1W Performance:
-3.18%
1M Performance:
+3.24%
6M Performance:
-9.47%
1Y Performance:
+65.92%
1-Day Range:
Value
$250.35
$260.00
1-Week Range:
Value
$245.96
$277.85
52-Week Range:
Value
$144.73
$304.39

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name
Name
Alnylam Pharmaceuticals Inc
Name
Phone
(617) 551-8200
Name
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Name
Employee
2,230
Name
Twitter
@alnylam
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
ALNY's Discussions on Twitter

Compare ALNY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.15 33.82B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
424.99 128.84B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
527.78 65.38B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
549.65 39.67B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ONC
Beigene Ltd Adr
231.99 27.60B 3.81B -644.79M -669.77M -6.24

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-31-25 Initiated Redburn Atlantic Buy
Mar-24-25 Upgrade JP Morgan Neutral → Overweight
Nov-12-24 Downgrade Wolfe Research Peer Perform → Underperform
Oct-16-24 Initiated Scotiabank Sector Outperform
Aug-16-24 Upgrade Goldman Neutral → Buy
Feb-16-24 Downgrade Goldman Buy → Neutral
Feb-15-24 Initiated Wolfe Research Peer Perform
Dec-08-23 Initiated Wells Fargo Equal Weight
Oct-11-23 Downgrade Oppenheimer Outperform → Perform
Sep-29-23 Initiated Raymond James Outperform
May-05-23 Upgrade BMO Capital Markets Market Perform → Outperform
Apr-26-23 Initiated SMBC Nikko Neutral
Mar-21-23 Initiated Bernstein Outperform
Jan-18-23 Initiated Canaccord Genuity Buy
Sep-09-22 Resumed Morgan Stanley Equal-Weight
Jul-13-22 Initiated Cantor Fitzgerald Neutral
Jun-27-22 Downgrade Guggenheim Buy → Neutral
Jun-07-22 Initiated William Blair Outperform
Apr-25-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-01-22 Initiated Citigroup Buy
Feb-03-22 Upgrade Guggenheim Neutral → Buy
Jan-03-22 Upgrade Piper Sandler Neutral → Overweight
Nov-22-21 Upgrade Goldman Neutral → Buy
Nov-22-21 Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-01-21 Upgrade Oppenheimer Perform → Outperform
Oct-04-21 Upgrade UBS Neutral → Buy
Aug-04-21 Downgrade Piper Sandler Overweight → Neutral
Feb-22-21 Downgrade Guggenheim Buy → Neutral
Feb-12-21 Downgrade Citigroup Buy → Neutral
Feb-12-21 Reiterated H.C. Wainwright Buy
Jan-25-21 Downgrade BMO Capital Markets Outperform → Market Perform
Sep-30-20 Resumed Berenberg Hold
Sep-08-20 Initiated Citigroup Buy
Aug-11-20 Downgrade Oppenheimer Outperform → Perform
May-13-20 Initiated RBC Capital Mkts Sector Perform
May-07-20 Downgrade JP Morgan Overweight → Neutral
Apr-24-20 Resumed Evercore ISI Outperform
Mar-19-20 Initiated Berenberg Buy
Dec-19-19 Reiterated Chardan Capital Markets Buy
Nov-20-19 Initiated Oppenheimer Outperform
Nov-13-19 Initiated BofA/Merrill Buy
May-23-19 Resumed Goldman Neutral
Apr-12-19 Initiated Evercore ISI Outperform
Mar-06-19 Upgrade Evercore ISI In-line → Outperform
Mar-05-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-23-19 Initiated UBS Neutral
Oct-01-18 Initiated Cantor Fitzgerald Overweight
Aug-13-18 Reiterated Stifel Buy
Aug-07-18 Upgrade Stifel Hold → Buy
May-04-18 Reiterated Stifel Hold
Mar-28-18 Initiated Evercore ISI In-line
View All

Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News

pulisher
May 09, 2025

‘Our bodies are art’: Alnylam campaign uses dance to tell patient’s story - Medical Marketing and Media

May 09, 2025
pulisher
May 09, 2025

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) - Becker's Hospital Review

May 09, 2025
pulisher
May 09, 2025

RNA Therapy Market Booms Amid Advancements in mRNA and Gene - openPR.com

May 09, 2025
pulisher
May 09, 2025

Vir posts mid-stage trial data for Hep B drug (VIR:NASDAQ) - Seeking Alpha

May 09, 2025
pulisher
May 08, 2025

$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today - Benzinga

May 08, 2025
pulisher
May 08, 2025

LEQVIO Strengthens Position as Leader in Cholesterol-Lowering Therapies Across Seven Major Markets | DelveInsight - ADVFN

May 08, 2025
pulisher
May 08, 2025

Dysautonomia Market Forecasted to Surge in Coming Years, - openPR.com

May 08, 2025
pulisher
May 08, 2025

Porphyria Treatment Market Grows with Targeted Rare Disease - openPR.com

May 08, 2025
pulisher
May 08, 2025

Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications - Pharma Voice

May 08, 2025
pulisher
May 08, 2025

Possible Bearish Signals With Alnylam Pharmaceuticals Insiders Disposing Stock - Yahoo Finance

May 08, 2025
pulisher
May 07, 2025

U.S. Transthyretin Amyloidosis Treatment Market Set to Witness - openPR.com

May 07, 2025
pulisher
May 07, 2025

Coagulation factor deficiency Market: Epidemiology, - openPR.com

May 07, 2025
pulisher
May 06, 2025

Alnylam Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - simplywall.st

May 06, 2025
pulisher
May 06, 2025

H.C. Wainwright maintains Alnylam stock Buy rating, $500 target By Investing.com - Investing.com UK

May 06, 2025
pulisher
May 06, 2025

Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress - ADVFN

May 06, 2025
pulisher
May 05, 2025

Alnylam to Webcast Presentation at BofA Securities 2025 Health C - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference - BioSpace

May 05, 2025
pulisher
May 05, 2025

Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference | ALNY Stock News - GuruFocus

May 05, 2025
pulisher
May 04, 2025

Analyst Estimates: Here's What Brokers Think Of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its First-Quarter Report - Yahoo Finance

May 04, 2025
pulisher
May 03, 2025

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2025 Earnings Call Transcript - Insider Monkey

May 03, 2025
pulisher
May 02, 2025

Alnylam Pharmaceuticals (ALNY) Target Price Raised by UBS | ALNY Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk - Benzinga

May 02, 2025
pulisher
May 02, 2025

Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y - The Globe and Mail

May 02, 2025
pulisher
May 02, 2025

UBS Boosts Alnylam (ALNY) Price Target Amid Promising Early Launch Trends | ALNY Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Alnylam Pharmaceuticals (ALNY) Target Price Raised to $325 by Ch - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Alnylam Pharmaceuticals (ALNY) Target Price Raised to $325 by Chardan Capital | ALNY Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga

May 02, 2025
pulisher
May 02, 2025

UBS Adjusts Alnylam Pharmaceuticals Price Target to $349 From $331, Maintains Buy Rating - marketscreener.com

May 02, 2025
pulisher
May 02, 2025

Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT In - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Alnylam Pharmaceuticals Inc (ALNY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and ... - Yahoo

May 02, 2025
pulisher
May 02, 2025

Alnylam Pharmaceuticals Inc (ALNY) Q1 2025 Earnings Call Highlig - GuruFocus

May 02, 2025
pulisher
May 01, 2025

Alnylam: Q1 Earnings Snapshot - MySA

May 01, 2025
pulisher
May 01, 2025

Alnylam Earnings: Launch of Amvuttra for ATTR-CM Underway; Fair Value Up to $245 From $223 - Morningstar

May 01, 2025
pulisher
May 01, 2025

Narrow-Moat Alnylam's Strong Patient Uptake Drives Growth; Diverse Pipeline Makes Progress - Morningstar

May 01, 2025
pulisher
May 01, 2025

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia - Seeking Alpha

May 01, 2025
pulisher
May 01, 2025

Alnylam Pharmaceuticals Reports Strong Start to 2025 - TipRanks

May 01, 2025
pulisher
May 01, 2025

Alnylam Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat

May 01, 2025
pulisher
May 01, 2025

Alnylam (ALNY): Price Target Raised Amid Promising Amvuttra Laun - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Alnylam Pharmaceuticals (ALNY) Reports Strong Q1 2025 Growth - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Alnylam Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:ALNY) - Seeking Alpha

May 01, 2025
pulisher
May 01, 2025

$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today - Benzinga

May 01, 2025
pulisher
May 01, 2025

Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

Earnings call transcript: Alnylam Q1 2025 beats EPS forecast, stock drops - Investing.com

May 01, 2025
pulisher
May 01, 2025

Alnylam Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 01, 2025
pulisher
May 01, 2025

Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

Alnylam Q1 2025 slides: 28% revenue growth as AMVUTTRA drives TTR franchise expansion - Investing.com

May 01, 2025
pulisher
May 01, 2025

Alnylam Q1 Non-GAAP Net Loss Narrows, Revenue Rises - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

ALNYLAM PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView

May 01, 2025
pulisher
May 01, 2025

We Take A Look At Why Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) CEO Has Earned Their Pay Packet - simplywall.st

May 01, 2025
pulisher
Apr 30, 2025

Judge Keeps Pfizer Foe's COVID Vaccine Patent Case Alive - Law360

Apr 30, 2025
pulisher
Apr 30, 2025

Novartis to acquire Regulus in deal for kidney disease drug - BioPharma Dive

Apr 30, 2025

Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$549.65
price down icon 3.42%
biotechnology ONC
$231.99
price down icon 1.67%
$92.77
price down icon 2.12%
$23.96
price down icon 2.80%
$33.15
price up icon 0.15%
Cap:     |  Volume (24h):